The Technical Analyst
Redhill Biopharma Ltd [RDHL]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Redhill Biopharma Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
5.85% $0.452
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 13.01 mill |
| EPS: | 4.00 |
| P/E: | 0.110 |
| Earnings Date: | Jun 10, 2024 |
| SharesOutstanding: | 28.78 mill |
| Avg Daily Volume: | 1.230 mill |
| RATING 2024-04-19 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Strong Buy | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0.110 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE 0.110 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.405 - 0.493 ( +/- 9.79%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.452
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.452
Forecast 2: 16:00 - $0.452
Forecast 3: 16:00 - $0.452
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.452 (5.85% ) |
| Volume | 0.329 mill |
| Avg. Vol. | 1.230 mill |
| % of Avg. Vol | 26.76 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RDHL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:27 | sell | $0.533 | N/A | Active |
|---|
RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Latest Press Releases
2024-04-08 09:23:00 - Press Release
Redhill Biopharma Announces Full-year 2023 Results And Operational Highlights
Redhill continues corporate transformation to focus on u.s. government-funded pipeline development in underserved, sizeable therapeutic areas with a disciplined cost-base focused externally funded r&d: opaganib for nuclear and chemical medical countermeasure (nih funding): selected for evaluation by two u.s. government countermeasures programs for acute radiation syndrome (ars) and sulfur mustard exposure. nuclear and chemical incident response strategies are characterized by significant government stockpiling of approved agents opaganib for ebola (u.s. army funding): u.s. army studies suggest opaganib is the first host-directed molecule to show activity in vivo in ebola virus disease, delivering a statistically significant increase in survival; separately, opaganib demonstrated robust synergistic effect in vitro when combined with remdesivir (veklury®; gilead sciences, inc...
2024-04-02 07:00:00 - Press Release
Redhill Biopharma Announces $1.25 Million Registered Direct Offering At A Premium To Market Price
Tel aviv, israel and raleigh, n.c. , april 2, 2024 /prnewswire/ -- redhill biopharma ltd.
2024-03-11 07:00:00 - Press Release
Redhill Announces New Uspto Patent Covering Talicia® Through 2034
U.s. patent and trademark office (uspto) issues new patent covering talicia 1 as an all-in-one treatment of helicobacter pylori (h. pylori), supporting talicia protection until february 12, 2034 this new patent adds to the existing strong intellectual property portfolio protecting talicia, including composition of matter and other patents and fda-granted data exclusivities granted under the gain qidp designation and section 505(b)(2) talicia is the only fda-approved rifabutin-containing all-in-one therapy for the eradication of h.
2024-03-05 07:00:00 - Press Release
Redhill's Opaganib Selected For Evaluation By Barda And Nih Countermeasures Programs
The u.s. government's chemical medical countermeasures (chem mcm) program and chemical countermeasures research program (ccrp), managed respectively by aspr/barda and nih/niaid, in collaboration with battelle[1], have selected opaganib for evaluation as a potential medical countermeasure (mcm) against sulfur mustard exposure opaganib, a novel oral small molecule, is the first sphingosine kinase-2 ( sphk2) inhibitor investigational drug targeting sphingolipid metabolism to be evaluated as a chemical countermeasure selection for the therapeutic testing/screening program, following opaganib's previous acceptance into the radiation and nuclear countermeasures program (rncp) for acute radiation syndrome (ars), provides the potential to see broad activity across both radiation and sulfur mustard injuries opaganib has five-year shelf-life and is easy to administer and distribute for use against potential chemical weapon attack, if approved by the u...
2024-01-26 12:46:00 - Press Release
Redhill Biopharma Announces Closing Of $8 Million Registered Direct Offering
Tel aviv, israel and raleigh, n.c., jan. 26, 2024 /prnewswire/ -- redhill biopharma ltd.
Latest News
2023-12-20 10:34:54 - PennyStocks
4 Penny Stocks To Buy For Under $5
Beyond blue chips, small-cap penny stocks with prices under $5 per share offer thrilling upside for risk-tolerant investors, especially when economic tailwinds bolster markets. This guide spotlights prime penny stock opportunities primed to soar past $5 into small-cap territory in 2024 as their innovative businesses flourish.
2023-12-20 09:13:00 - Market Watch
RedHill Biopharma shares jump as Ebola treatment shows promise
RedHill Biopharma Ltd. American depositary receipts RDHL, +8.20% climbed 10% premarket on Wednesday after the company said two of its experimental drugs, when individually combined with remdesivir, showed promise in combating the Ebola virus.
2023-12-01 06:41:00 - Market Watch
Bill Gross says beaten-down mortgage plays may thrive — and offer huge yields
Early Friday futures suggest stocks will start December on a cautious note. The last month of the year tends to be positive for Wall Street, though it will be some feat if it can beat November's 8.9% jump for the S&P 500 SPX.
2023-11-30 09:08:26 - InvestorPlace
Why Is Redhill Biopharma (RDHL) Stock Down 27% Today?
Redhill Biopharma (NASDAQ: RDHL ) stock is sliding lower on Thursday but only after the company's shares come off of a recent rally. Shares of RDHL stock saw major gains earlier in the week.
2023-11-28 11:54:40 - Invezz
RedHill Biopharma (RDHL) gained 216% after FDA approvals: Buy Now!
RedHill Biopharma Ltd (NASDAQ: RDHL) just received an exclusive licence for the commercialisation of Talicia. The drug is used to treat Helicobacter Pylori infections, commonly known as H- Pylori.
2023-11-27 13:41:34 - InvestorPlace
5 Investors Betting Big on RedHill Biopharma (RDHL) Stock
Amid a slow start to the new week, specialty drug developer RedHill Biopharma (NASDAQ: RDHL ) dramatically enlivened the mood, skyrocketing over 180% during the early afternoon session. Catapulting sentiment was regulatory approval for Talicia, a therapeutic designed to target helicobacter pylori (H.
2023-07-21 07:32:00 - Market Watch
RedHill Biopharma's stock soars 10% after company gets U.S. funding to develop treatment for radiation sickness
RedHill Biopharma Ltd.'s stock RDHL, +1.65% soared 10% premarket after the company said it has received a further $1.7 million in U.S. government funding for its partner, Apogee, to develop a treatment for gastrointestinal acute radiation syndrome.
2023-01-28 06:00:00 - PennyStocks
The Impact of Market Trends on Penny Stocks Performance
Understand how market trends impact penny stocks The post The Impact of Market Trends on Penny Stocks Performance appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-01-27 07:46:02 - InvestorPlace
Why Is Redhill Biopharma (RDHL) Stock Up 32% Today?
Redhill Biopharma (NASDAQ: RDHL ) stock is rocketing higher on Friday after getting positive patent news from the U.S. Patent and Trademark Office (USPTO). The USPTO issued a Notice of Allowance that grants the company a patent for RHB-204's treatment methods.
2022-10-20 14:18:11 - Zacks Investment Research
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.